About MARAbio
MARAbio is a company based in Salt Lake City (United States) founded in 2016 by Judy Van De Water and Michael S Paul. MARAbio has raised $19.06 million across 1 funding round from investors including MAK Capital. MARAbio offers products and services including MARA Blood Test. MARAbio operates in a competitive market with competitors including Lineagen, Linus Biotechnology, Pediatric Bioscience, SensOmics and NeuroPoint Dx, among others.
- Headquarter Salt Lake City, United States
- Founders Judy Van De Water, Michael S Paul
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$19.06 M (USD)
in 1 rounds
-
Latest Funding Round
$19.06 M (USD), Series A
Sep 16, 2024
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of MARAbio
MARAbio offers a comprehensive portfolio of products and services, including MARA Blood Test.
Blood test to detect antibodies predicting autism risk in children.
People of MARAbio
Unlock access to complete
Unlock access to complete
Funding Insights of MARAbio
MARAbio has successfully raised a total of $19.06M through 1 strategic funding round. The most recent funding activity was a Series A round of $19.06 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in MARAbio
MARAbio has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include MAK Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked |
Investor details for MARAbio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MARAbio
Investment portfolio details for MARAbio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - MARAbio
Detailed financials for MARAbio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Marabio Comparisons
Peer comparison for MARAbio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MARAbio
MARAbio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Lineagen, Linus Biotechnology, Pediatric Bioscience, SensOmics and NeuroPoint Dx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Sequencing-based diagnostic tests and services for autism are provided.
|
|
| Locked | Locked | Locked |
Developer of diagnostic tests for central nervous system and gastrointestinal disorders
|
|
| Locked | Locked | Locked |
Provides blood biomarker-based diagnostics for autism spectrum disorders.
|
|
| Locked | Locked | Locked |
Precision medicine for children's health is provided through genomic integration.
|
|
| Locked | Locked | Locked |
Metabolomics for neuro-developmental disorders
|
Detailed competitors of MARAbio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Marabio
Complete news archive for MARAbio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MARAbio
MARAbio was founded in 2016 and raised its 1st funding round 8 years after it was founded.
MARAbio is headquartered in Salt Lake City, United States. It is registered at Salt Lake City, Utah, United States.
Michael S Paul is the current CEO of MARAbio. They have also founded this company.
MARAbio is a funded company, having raised a total of $19.06M across 1 funding round to date.
MARAbio was founded in 2016 in Salt Lake City, United States, within the biotechnology sector focused on diagnostic tools. Precision blood tests are developed to identify specific autoantibodies in women, which are linked to autism development in children. Operations center on early risk assessment through this technology, supporting maternal health evaluations in clinical settings across the U.S.
MARAbio's top competitors include Linus Biotechnology, Lineagen and FBB Biomed.
MARAbio offers MARA Blood Test.
MARAbio has 1 investor. Key investors include MAK Capital.